Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Seminars in liver disease (Print)

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/S-2003-41630PMID 12934163
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy.

  2002cited by this paper
• Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications

  2002cited by this paper
• A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C

  2001cited by this paper
• Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a.

  2001cited by this paper
• Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.

  2000influential reference
• Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus.

  2000cited by this paper
• Pegylated interferon‐α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data

  2000cited by this paper
• Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

  1998cited by this paper
• Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy

  1998cited by this paper
• Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo

  1996cited by this paper

• Bistability in virus–host interaction networks underlies the success of hepatitis C treatments

  2020cites this paper
• The review of differential equation models of HBV infection dynamics.

  2019cites this paper
• A New Age-Structured Multiscale Model of the Hepatitis C Virus Life-Cycle During Infection and Therapy With Direct-Acting Antiviral Agents

  2018cites this paper
• Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon‐free treatment era

  2018cites this paper
• A Pharmacokinetic/Viral Kinetic Model to Evaluate Treatment of Chronic HCV Infection with a Non-Nucleoside Polymerase Inhibitor

  2018cites this paper
• Mathematical Modeling: Solving Equations to Measure Viral Diseases—Math Rules

  2016cites this paper
• Modelling hepatitis C therapy—predicting effects of treatment

  2015cites this paper
• Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome.

  2015cites this paper
• A Computational Model of Inhibition of HIV-1 by Interferon-Alpha

  2015cites this paper
• Viral kinetic modeling: state of the art

  2014influential citation
• A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis

  2014cites this paper
• Viral Kinetic Modeling of Chronic Hepatitis C and B Infection

  2013cites this paper
• Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model

  2013cites this paper
• Dynamics of hepatitis C under optimal therapy and sampling based analysis

  2013cites this paper
• Modeling Quasispecies and Drug Resistance in Hepatitis C Patients Treated with a Protease Inhibitor

  2012cites this paper
• Optimal Therapy of Hepatitis C Dynamics and Sampling Based Analysis

  2011cites this paper
• Hepatitis C infection in the human liver: Viral dynamics, treatment and related side-effects

  2011cites this paper
• Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy

  2011cites this paper
• Pharmacokinetic and pharmacodynamic modeling of pegylated-interferon alfa.

  2010cites this paper
• A perspective on modelling hepatitis C virus infection

  2010cites this paper
• Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus

  2010cites this paper
• Statistical Models of Treatment Effects in Chronic Hepatitis B and C

  2010cites this paper
• Modeling Hepatitis C Virus Kinetics under Therapy using Pharmacokinetic and Pharmacodynamic Information

  2010cites this paper
• Administration continue par voie sous-cutanée d'interféron-α à des patients infectés par le virus de l'hépatite c

  2010cites this paper
• Evaluating treatment of hepatitis C for hemolytic anemia management.

  2010cites this paper
• Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling.

  2010cites this paper
• Pharmacokinetic-Pharmacodynamic Modeling of Alpha Interferon Response Induced by a Toll-Like 7 Receptor Agonist in Mice (cid:1)

  2010cites this paper
• Rapid emergence of hepatitis C virus protease inhibitor resistance is expected

  2009cites this paper
• Dynamical biocontrol systems: insights through mechanistic modelling

  2009cites this paper
• Optimal efficacy of ribavirin in the treatment of hepatitis C

  2009cites this paper
• Mathematical modeling of HCV infection and treatment.

  2009cites this paper
• Modeling HCV kinetics under therapy using PK and PD information

  2009influential citation
• OPTIMALLY CONTROLLED TREATMENT STRATEGY USING INTERFERON AND RIBAVIRIN FOR HEPATITIS C

  2009cites this paper
• Pharmacokinetic-Pharmacodynamic Modeling of Alpha Interferon Response Induced by a Toll-Like 7 Receptor Agonist in Mice

  2009cites this paper
• Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics

  2009cites this paper
• Advances in theMathematical ModellingofHepatitisCVirusDynamics

  2008cites this paper
• Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon α‐2b

  2008cites this paper
• Hepatitis C viral kinetics in special populations

  2008cites this paper
• Modelling hepatitis C virus kinetics during treatment with pegylated interferon α‐2b: errors in the estimation of viral kinetic parameters

  2008cites this paper
• A Hepatitis C Viral Kinetic Model that Allows for Time-Varying Drug Effectiveness

  2008cites this paper
• Modelling of viral dynamics in hepatitis B and hepatitis C clinical trials

  2008cites this paper
• Estimating drug efficacy and viral dynamic parameters: HIV and HCV

  2008cites this paper
• Virodynamic Predictors of Response to Pegylated Interferon and Lamivudine Combination Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis B

  2008cites this paper
• Immune Modulating Therapy and its Viral Kinetics in Chronic Hepatitis B

  2008cites this paper
• Advances in the Mathematical Modelling of Hepatitis C Virus Dynamics

  2008cites this paper
• HOST GENETIC VARIANTS, TREATMENT OUTCOMES AND METABOLIC COMPLICATIONS IN HEPATITIS C VIRUS GENOTYPE-1

  2008cites this paper
• Improved detection of acute HIV-1 infection in sub-Saharan Africa: development of a risk score algorithm

  2007cites this paper
• Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV‐coinfected patients

  2007cites this paper
• Modelling of Early Viral Kinetics and Pegylated Interferon-α2b Pharmacokinetics in Patients with HBeAg-Positive Chronic Hepatitis B

  2007cites this paper
• The American Association for the Study of Liver Diseases: New Perspectives in the Treatment of Hepatitis C

  2006cites this paper
• Review article: predicting response in hepatitis C virus therapy

  2006cites this paper
• The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus

  2006cites this paper
• Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.

  2006cites this paper
• Workshop report The American Association for the Study of Liver Diseases: new perspectives in the treatment of hepatitis C

  2006cites this paper
• The kinetics of hepatitis C virus

  2006cites this paper
• Viral kinetics in the treatment of chronic hepatitis C

  2006cites this paper
• Pharmacodynamics of PEG‐IFN α differentiate HIV/HCV coinfected sustained virological responders from nonresponders

  2006cites this paper
• New kinetic models for the hepatitis C virus

  2005cites this paper
• Editorial Mutagenic effects of ribavirin in vivo

  2005cites this paper
• Ribavirin mutagenesis: Hidden clues in mathematical models

  2005cites this paper
• Mutagenic effects of ribavirin in vivo.

  2005cites this paper
• A viral kinetic study using pegylated interferon alfa‐2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative

  2005cites this paper
• Estudo da cinética viral do vírus da hepatite C em pacientes co-infectados com o HIV

  2005cites this paper
• Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.

  2005cites this paper
• Modelling how ribavirin improves interferon response rates in hepatitis C virus infection

  2004cites this paper
• Virus Dynamics and Immune Responses During Treatment in Patients Coinfected With Hepatitis C and HIV

  2004cites this paper
• Hepatitis C viral kinetics

  2004cites this paper
• Hepatitis-C-Virus - Viruskinetik und Resistenzmechanismen

  2004cites this paper
• Update on viral kinetics and hcv antiviral therapy

  2004cites this paper
• Pharmacokinetics and Pharmacodynamics of PEGylated IFN-β 1a Following Subcutaneous Administration in Monkeys

  2004cites this paper
• [Hepatitis C-virus --virus kinetics and resistance mechanisms].

  2004cites this paper
• A sheep in wolf's clothing

  2003cites this paper
• Reply

  2003cites this paper
• Effect of SOF/VEL Antiviral Therapy for HCV Treatment: A Control Theoretic Approach

  year unknowncites this paper